Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors

Blood

Volumn 121, Issue 18, 2013, Pages 3675-3681

  Altman, Jessica K ^a,b   Szilard, Amy ^a   Konicek, Bruce W ^c   Iversen, Philip W ^c   Kroczynska, Barbara ^a   Glaser, Heather ^a   Sassano, Antonella ^a   Vakana, Eliza ^a   Graff, Jeremy R ^c   Platanias, Leonidas C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CERCOSPORAMIDE; CYTARABINE; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHOTRANSFERASE; PROTEIN MNK; UNCLASSIFIED DRUG; WATER; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; ATP7A PROTEIN, HUMAN; BENZOFURAN DERIVATIVE; CATION TRANSPORT PROTEIN; PROTEIN KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CLONOGENIC ASSAY; COLONY FORMATION; COLONY FORMING UNIT; COLONY FORMING UNIT L; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER STEM CELL; CELL STRAIN K 562; CELL STRAIN U937; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOFURANS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MICE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84879720960     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-477216     Document Type: Article

References (34)

1. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101(12):4667-4679. (Pubitemid 36857719)
2. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs. 2009;18(9):1333-1349.
3. Khokhar NZ, Altman JK, Platanias LC. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol. 2011;23(6):578-586.
4. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26(22):3100-3112. (Pubitemid 46763006)
5. Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget. 2012;3(2):118-131.
6. Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci. 2008;13:5359-5373.
7. Fukunaga R, Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 1997;16(8):1921-1933. (Pubitemid 27170953)
8. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997;16(8):1909-1920. (Pubitemid 27170952)
9. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol. 1999;19(3):1871-1880. (Pubitemid 29098245)
10. Scheper GC, Morrice NA, Kleijn M, Proud CG. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol. 2001;21(3):743-754. (Pubitemid 32104723)
11. Dolniak B, Katsoulidis E, Carayol N, et al. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem. 2008;283(18):12034-12042.
12. Joshi S, Kaur S, Redig AJ, et al. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci USA. 2009;106(29):12097-12102.
13. Joshi S, Sharma B, Kaur S, et al. Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis. J Biol Chem. 2011;286(8):6017-6026.
14. Fischer PM. Cap in hand: targeting eIF4E. Cell Cycle. 2009;8(16):2535-2541.
15. Phillips A, Blaydes JP. MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA. Oncogene. 2008;27(11):1645-1649. (Pubitemid 351347869)
16. Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res. 2004;64(23):8639-8642. (Pubitemid 39552077)
17. Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R, Mak TW. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA. 2010;107(32):13984-13990.
18. Wendel HG, Silva RL, Malina A, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21(24):3232-3237. (Pubitemid 350277750)
19. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24(15):6539-6549. (Pubitemid 38944335)
20. Altman JK, Glaser H, Sassano A, et al. Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. Mol Pharmacol. 2010;78(4):778-784.
21. Konicek BW, Stephens JR, McNulty AM, et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 2011;71(5):1849-1857.
22. Kroczynska B, Kaur S, Katsoulidis E, et al. Interferon-dependent engagement of eukaryotic initiation factor 4B (eIF4B) via S6K- and RSK mediated signals. Mol Cell Biol. 2009;29(10):2865-2875.
23. Kroczynska B, Sharma B, Eklund EA, Fish EN, Platanias LC. Regulatory effects of programmed cell death 4 (PDCD4) protein in ISG expression and generation of Type I interferon-responses. Mol Cell Biol. 2012;32(14):2809-2822.
24. Sassano A, Katsoulidis E, Antico G, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res. 2007;67(9):4524-4532. (Pubitemid 46815104)
25. Woodard J, Sassano A, Hay N, Platanias LC. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res. 2008;14(14):4640-4649.
26. Malina A, Cencic R, Pelletier J. Targeting translation dependence in cancer. Oncotarget. 2011;2(1-2):76-88.
27. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA. 2004;101(52):18105-18110. (Pubitemid 40054081)
28. Culjkovic B, Topisirovic I, Borden KL. Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle. 2007;6(1):65-69. (Pubitemid 46173883)
29. Borden KL, Culjkovic-Kraljacic B. Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma. 2010;51(10):1805-1815.
30. Graff JR, Konicek BW, Vincent TM, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 2007;117(9):2638-2648. (Pubitemid 47494364)
31. Hong DS, Kurzrock R, Oh Y, et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011;17(20):6582-6591.
32. Assouline S, Culjkovic B, Cocolakis E, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-ofprinciple clinical trial with ribavirin. Blood. 2009;114(2):257-260.
33. Altman JK, Sassano A, Kaur S, et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res. 2011;17(13):4378-4388.
34. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065-3074.